Swiss pharmaceutical giant Roche on Thursday posted better-than-expected net income for the first half of 2025 amid strong sales of asthma and breast cancer treatments.
Danaher posted higher third-quarter earnings and said it expects pharmaceutical companies to increase research-and-development spending as tariff uncertainty eases. “We do see the tariff situation ...
CEO David Zaccardelli highlighted the continued success of the Ohtuvayre launch for COPD maintenance treatment, with net product sales of $71.3 million in Q1 2025, nearly doubling from the previous ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback